Abundance Wealth Counselors Has $369,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Abundance Wealth Counselors boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 14.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,288 shares of the company’s stock after buying an additional 541 shares during the period. Abundance Wealth Counselors’ holdings in Novo Nordisk A/S were worth $369,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. AQR Capital Management LLC boosted its stake in Novo Nordisk A/S by 110.5% in the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after purchasing an additional 9,012 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S in the second quarter worth $25,000. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Novo Nordisk A/S by 45.8% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,664 shares of the company’s stock valued at $3,378,000 after buying an additional 7,430 shares in the last quarter. Centaurus Financial Inc. raised its position in Novo Nordisk A/S by 98.5% during the second quarter. Centaurus Financial Inc. now owns 7,175 shares of the company’s stock valued at $1,024,000 after buying an additional 3,560 shares during the period. Finally, Capital Market Strategies LLC lifted its stake in Novo Nordisk A/S by 1.5% in the 3rd quarter. Capital Market Strategies LLC now owns 9,894 shares of the company’s stock worth $1,178,000 after acquiring an additional 150 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 1.2 %

Novo Nordisk A/S stock opened at $84.36 on Friday. The company has a market capitalization of $378.56 billion, a P/E ratio of 27.30, a P/E/G ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The firm’s fifty day simple moving average is $93.56 and its 200-day simple moving average is $113.22. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.